Abstract 614P
Background
Programmed Death Ligand-1 (PD-L1) is expressed in most type of cancer cells, including osteosarcoma. However, the role of PD-L1 expression in prognosis of osteosarcoma patients remains unclear. Thus, this study aims to investigate the association between PD-L1 expression and prognosis of Osteosarcoma patients.
Methods
Data was gathered from PubMed, PMC, and ScienceDirect databases on September 08, 2022, using keywords associated with PD-L1, Osteosarcoma in relation to the prognosis, which is measured by overall survival (OS), progression free survival (PFS), and event free survival (EFS). Publications included are associated with Osteosarcoma patients that are limited to English manuscripts within the last 10 years. Review articles, publications without full paper, and case report studies are excluded. The quality of each included study was assessed using the Newcastle Ottawa Scale (NOS), JBI Critical Appraisal for Quasi Experimental Studies, and Grading of recommendations, assessment, development, and evaluations (GRADE).
Results
A total of 7 studies consisting of 289 Osteosarcoma patients were included. All 6 studies have good quality based on NOS and one study categorized as include based on JBI. All 7 studies showed that high expression of PD-L1 correlates with poor prognosis of Osteosarcoma patients. Pooled analysis showed that high PD-L1 expression correlates with inferior OS (HR=2.03; 95%CI, 1.12-3.69; p=0.02) and PFS (HR= 1.18; 95%CI, 1.06-1.31; p=0.003). However, no significant association between PD-L1 expression and EFS (HR=1.05; 95%CI, 0.40-2.75; p=0.92). Based on GRADE, the result of this study is moderate in quality, as there is no inconsistency in results and publication biases are minimal.
Conclusions
Current studies demonstrated that high PD-L1 expression is associated with inferior OS and PFS, but not EFS in osteosarcoma patients, which warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract